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Virology, University of Vienna, Austria; Swiss Serum and VaccineGerhard Wiedermann, Christian Herzog,
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The effects of concomitant administration of antimalarial drugs, oral polio vaccine, or yellow
fever vaccine on the immune response elicited by the Vibrio cholerae CVD103-HgR and Salmonella
typhi Ty21a live oral vaccines were investigated. Healthy adults were immunized with CVD103-
HgR alone or combined with Ty21a. Subjects were randomized to simultaneously receive mefloquine,
chloroquine or proguanil, or oral polio or yellow fever vaccine. The vibriocidal antibody seroconver-
sion rate was significantly reduced (P  .008) only in the group that received chloroquine with the
CVD103-HgR. The geometric mean vibriocidal antibody titer was significantly decreased in the
groups that received chloroquine (P  .001) or mefloquine (P  .02) compared with titers in groups
that received CVD103-HgR alone. However, similar immunosuppressive effects were not observed
in the groups immunized with Ty21a and CVD103-HgR. Only the concomitant administration of
proguanil effected a significant (P  .013) decline in the anti–S. typhi lipopolysaccharide antibody
response. These results indicate that chloroquine and proguanil should not be simultaneously admin-
istered with the CVD103-HgR and Ty21a vaccine strains, respectively.
Live oral attenuated vaccines against polio, typhoid fever, administration of multiple oral vaccines could increase the fre-
quency and severity of adverse reactions compared with thoseand cholera are licensed for human use [1±3]. These vaccines
have the distinct advantage of stimulating local intestinal im- when vaccines are given individually.
We have recently demonstrated that the Ty21a and CVD103-munity, thereby blocking infection at the earliest possible stage.
In addition, their ease of administration greatly facilitates mass HgR vaccine strains could be simultaneously administered
without compromising safety or immunogenicity of eithervaccination campaigns. Adverse reactions associated with the
use of the Salmonella typhi Ty21a and Vibrio cholerae strain [9, 10]. This ®nding paves the way for the development
of additional multivalent live oral vaccine formulations.CVD103-HgR vaccine strains are infrequent, mild, and tran-
sient [4, 5]. These products have served as models for the future The effects of simultaneous administration of live vaccines
or the concomitant use of antimalarial drugs with antibacterialdevelopment of vaccines against a wide variety of bacterial and
viral enteric pathogens. activity on the immune response to immunization have not
been studied in great detail. Chloroquine has been shown toIn order to induce a protective immune response, live vac-
cines must undergo a limited degree of replication in vivo. signi®cantly decrease the immune response to parenterally ad-
ministered human diploid cell±derived rabies vaccine [11].Interference with this process would be expected to diminish
the level of immunity provided. For example, the concomitant When administered together, parenteral cholera and yellow fe-
ver vaccines have an immunosuppressive effect on each otheruse of antibiotics or antimalarial drugs with activity against
live bacterial vaccine strains could markedly suppress their [12]. The fact that many travelers are often prescribed ⁄1 of
the above-mentioned vaccines together with an antimalarialmultiplication, hence lowering the level of protection conferred
[5±8]. Another potential concern is that the coadministration drug makes these issues of signi®cant practical importance.
We therefore conducted a study among Austrian travelers toof ⁄2 live oral vaccines could interfere with the immune re-
sponse to ⁄1 of the vaccine strains. Finally, the simultaneous determine the effect of simultaneously administering various
vaccines and antimalarial drugs on the immune response to the
Ty21a and CVD103-HgR vaccine strains.
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The study protocol was approved by the Ethical Committee, University of
Materials and MethodsVienna Medical School, Vienna, Austria. Written informed consent was ob-
tained from each volunteer.
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The Journal of Infectious Diseases 1997;175:871±5
aluminum foil sachet. One chamber contained 5 1 108 cfu ofq 1997 by The University of Chicago. All rights reserved.
0022±1899/97/7504±0019$01.00 CVD103-HgR alone or in combination with 5 1 109 cfu of
/ 9d21$$ap12 02-03-97 16:27:02 jinfa UC: J Infect
872 Kollaritsch et al. JID 1997;175 (April)
Ty21a. The other chamber contained a buffer composed of 2.5 g Serologic analysis. Antibody titrations were done in a blinded
manner. Vibriocidal antibody titers were determined using a micro-of sodium bicarbonate and 1.65 g of ascorbic acid.
Trivalent oral polio vaccine (Polio Sabine Oral; SmithKline titer plate assay as previously described, using V. cholerae 569B
(classical, Inaba) as the test strain [13]. A signi®cant response wasBeecham, Riksensart, Belgium) was administered as a single 0.5-
mL dose. de®ned as a ⁄4-fold rise in titer over baseline. Anti±S. typhi IgG
and IgA lipopolysaccharide antibodies were quantitated using anYellow fever vaccine (Arilvax, lot no. 1/350; Burroughs Well-
come, Beckenham, UK) contained the attenuated 17D strain of ELISA as described elsewhere [14]. An increase of ⁄0.15 optical
density units over baseline was considered signi®cant.yellow fever virus. A single 0.5-mL subcutaneous injection was
administered in the deltoid area. Statistical analysis. Statistical differences in vibriocidal and
anti±S. typhi IgG response rates between groups were determinedAntimalarial drugs. Me¯oquine (Lariam F; Hoffmann-La-
Roche, Basel, Switzerland) was administered orally in tablet form by x2 analysis. Differences in the geometric mean antivibriocidal
titers between groups were determined using a one-tailed t test.(250 mg) at weekly intervals. Chloroquine (Resochin; Bayer, Lev-
erkusen, Germany) was administered in tablet form (2 tablets cor- The rate of adverse reactions between groups was analyzed using
x2 analysis with Yates's correction.responding to 250 mg of chloroquine diphosphate) at weekly inter-
vals. Proguanil (Paludrine; Zeneca, Maccles®eld, UK) was
administered orally (2 100-mg tablets) daily for 7 days.
ResultsMIC determinations. The in vitro MICs of me¯oquine, chlo-
roquine, and proguanil for the Ty21a and CVD103-HgR strains
Adverse reactions associated with immunization or the ad-
were determined by a standard tube dilution method. The MIC
ministration of antimalarial drugs (or both) are shown in tablewas de®ned as the lowest concentration of drug that resulted in
1. The overall rate of adverse events reported was compara-no visible growth after incubation at 377C for 24 h.
tively high, with such nonspeci®c events as malaise and head-Study design. Healthy men and women⁄18 years of age were
ache being reported by 50% of subjects in several groups.recruited from the student body of the University of Vienna. Exclu-
sion criteria included acute febrile illness, history of allergies, This can most likely be attributed to the fact that the volunteers
immunization against either cholera or typhoid fever within the were highly motivated to report any and all symptoms that
past 3 years, immunization against polio within the past 5 years, could be related to vaccination. The vast majority of reactions
previous vaccination against yellow fever, use of antibiotics within were transient, mild, and resolved without medical intervention.
7 days of initiating the study, treatment with immunosuppressive No concomitant treatment resulted in a statistically signi®cant
drugs, underlying immunode®ciency state, epilepsy, clinical de- higher rate for any type of adverse event.
pression, receipt of an experimental drug within the past 3 months,
The effect of concomitant administration of antimalarial
receipt of blood products within the preceding 3 months, use of
drugs or vaccines on the vibriocidal antibody response engen-b-blockers, acute or chronic gastrointestinal illness, pregnancy or
dered by CVD103-HgR alone or in combination with Ty21alactation, or current participation in another trial.
is shown in table 2. The MICs for me¯oquine, chloroquine,After being screened, the volunteers were randomized into
and proguanil against CVD103-HgR were 25 mg/mL, 500groups that received the following treatment regimens: Groups A±
F received a single dose of CVD103-HgR on day 1. Groups G± mg/mL, and 50 mg/mL, respectively. For subjects receiving
L received a single oral dose of the combined Ty21a and CVD103- CVD103-HgR alone, only the coadministration of chloroquine
HgR vaccines on day 1, with monovalent Ty21a given on days 3 resulted in a signi®cant (P  .008) reduction in the percent
and 5. Groups B and H also received a single dose of me¯oquine who responded with a signi®cant (⁄4-fold) rise in vibriocidal
on days 1 and 8. Groups C and I also received 2 chloroquine antibody titers. Analysis of postimmunization geometric mean
tablets on days 1 and 8. Groups D and J also received 2 tablets titers (GMTs) of vibriocidal antibody showed that both me¯o-
of proguanil on days 1±7. Groups E and K were immunized with
quine and chloroquine exerted suppressive effects. Of interest,
yellow fever vaccine on day 1. Groups F and L were immunized
the highest response rate, as gauged by both seroconversionagainst polio on day 1. There were 45 subjects in groups A and
rate and GMT, was seen in the group that also received yellowG; the remaining groups contained 30 persons. The subjects were
fever vaccine. In contrast to the above, no concomitant treat-instructed to fast for 1 h before and after vaccination. The Ty21a
ment was found to exert a deleterious effect upon either theand CVD103-HgR vaccines were suspended in 100 mL of water,
mixed with a spoon to yield a homogeneous suspension, and imme- vibriocidal seroconversion rate or postimmunization GMTs of
diately ingested. Other vaccines or antimalarial drugs were admin- subjects who received the combined CVD103-HgR plus Ty21a
istered just after ingestion of the ®rst dose of Ty21a or CVD103- vaccine formulation. In fact, the highest seroconversion rates
HgR (or both) vaccines. Venous blood samples were obtained at and GMTs were achieved in the groups that received me¯o-
immunization and 14 days later. Serum was collected, placed into quine or oral polio vaccine.
labeled, dated tubes, and stored at0207C. Subjects were instructed
To determine whether the negative effects of me¯oquine and
to record all adverse events on a report form for 7 days following
chloroquine on the vibriocidal antibody response in the groupthe initial immunization. Speci®cally, subjects were asked to note
that received only the CVD103-HgR vaccine were related tothe following symptoms: headache, malaise, nausea, vomiting, ab-
the relatively small sample size, the following analysis wasdominal discomfort, diarrhea, cutaneous reactions such as rash or
performed. To enlarge the sample size, values from groupspruritus, fever, and any other clinically relevant event potentially
related to the study drugs. with the same concomitant treatment, such as B and H, were
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Table 1. Adverse events following immunization with various combinations of vaccines and antimalarial drugs.
% reporting adverse reaction
Vaccine, Concomitant Abdominal
group (n) treatment Diarrhea Nausea Vomiting discomfort Headache Malaise Cutaneous
CVD 103-HgR
A (45) None 22.2 20 0 22.2 51.1 44.4 6.7
B (30) Me¯oquine 33.3 13.3 0 16.7 36.7 36.7 10
C (30) Chloroquine 10 13.3 3.3 28.3 36.7 33.3 3.3
D (30) Proguanil 30 36.7 6.7 23.3 56.7 50 6.7
E (30) Yellow fever vaccine 10 10 0 3.3 46.7 63.3 20
F (30) Oral polio vaccine 10 10 0 6.7 30 46.7 3.3
CVD-HgR/Ty21a
G (45) None 31 15.6 2.2 13.3 40 51.1 11.1
H (30) Me¯oquine 40 20 3.3 16.7 50 53.3 3.3
I (30) Chloroquine 20 23.3 0 23.3 63.3 30 0
J (30) Proguanil 30 33.3 0 10 40 53.3 10
K (30) Yellow fever vaccine 30 6.7 0 10 33.3 43.3 13.3
L (30) Oral polio vaccine 30 3.3 0 13.3 30 40 6.7
pooled and compared with the pooled values for the 2 control mL, respectively. Only proguanil was found to exert a signi®-
cant (P  .013) decrease upon the combined IgG or IgA serumgroups (A and G). Chloroquine was still found to signi®cantly
(P .014) lower the seroconversion rate and postimmunization anti±S. typhi lipopolysaccharide antibody response. Me¯o-
quine, which had the highest level of in vitro activity againstGMT (P  .001). Similarly, me¯oquine treatment resulted in
a slightly decreased vibriocidal GMT (P  .032), although the Ty21a, did not adversely affect the immune response engen-
dered by Ty21a, as gauged by the combined IgG or IgA re-seroconversion rates were virtually identical (88% vs. 87.5%)
between the pooled groups. Concurrent immunization with oral sponse rate. However, the IgG response was somewhat lower
in the group that received me¯oquine (table 3).polio vaccine or yellow fever vaccine did not impact the im-
mune response evoked by CVD103-HgR given alone or in
Discussioncombination with Ty21a.
The MICs for me¯oquine, chloroquine, and proguanil The current study demonstrated that the simultaneous admin-
istration of certain antimalarial drugs commonly given to trav-against Ty21a were 10 mg/mL, 500 mg/mL, and 200 mg/




Vaccine, group Concomitant treatment rate, no./total (%) P* Before After P*
CVD 103-HgR
A None 41/45 (91) Ð 28.9 1516 Ð
B Me¯oquine 24/30 (80) .05 19.5 597 .02
C Chloroquine 20/30 (67) .008 36.8 359 .001
D Proguanil 25/30 (83) .05 20 1064 .05
E Yellow fever vaccine 29/30 (97) .05 21.4 4256 .05
F Oral polio vaccine 27/30 (90) .05 21.4 1309 .05
CVD 103-HgR/Ty21a
G None 39/45 (87) Ð 21.3 806 Ð
H Me¯oquine 29/30 (97) .05 25.8 1470 .05
I Chloroquine 23/30 (77) .05 23.5 640 .05
J Proguanil 25/30 (83) .05 24.6 752 .05
K Yellow fever vaccine 25/30 (83) .05 15.9 864 .05
L Oral polio vaccine 28/30 (93) .05 21.9 1539 .05
NOTE. GMT  geometric mean titer.
* A vs. B±F or G vs. H±L for seroconversion rates and comparison of postimmunization antibody titers.
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Table 3. Effect of concomitant treatment with antimalarial drugs to an enhancement of the immune response elicited by
or CVD-HgR/Ty21a vaccine on the immune response to Salmonella CVD103-HgR when combined with Ty21a [10].
typhi Ty21a. The disparate ®ndings between in vitro and in vivo activity
of the antimalarial drugs evaluated may, in large part, be relatedAnti±S. typhi LPS response
to their pharmacokinetic properties. For example, me¯oquine(%)
Concomitant is rapidly adsorbed into the bloodstream (absorption half-life
Group treatment IgG IgA IgG or IgA P* of 0.36±2 h, manufacturer's information; Roche Laboratories,
Nutley, NJ). Since neither Ty21a nor CVD103-HgR enters the
G None 71.1 48.9 77.8 Ð
circulatory system, the duration of contact with these drugs isH Me¯oquine 50 50 70 .73
therefore most likely limited. The MIC values of proguanil doI Chloroquine 56.7 56.7 70 .73
J Proguanil 50 36.7 50 .01 not accurately re¯ect its in vivo activity since cycloguanil, a
K Yellow fever vaccine 66.7 56.7 76.7 .91 metabolite produced by the liver, is believed to be the active
L Oral polio vaccine 83.3 66.7 86.7 .86 form of this drug (unpublished data, Zeneca). Chloroquine has
been shown to suppress the immune response to even an inacti-NOTE. LPS  lipopolysaccharide.
* G vs. H±L for IgA or IgG antibody response rates. vated rabies vaccine [11]. This immunosuppressive effect may
be related to the fact that chloroquine is deposited in various
tissues, including lymphocytes, and can attain levels 2±700
times higher than those attained in plasma (unpublished data,elers may interfere with the immune response engendered by
the Ty21a or CVD103-HgR live oral vaccine strains. Serum Sano® Winthrop Pharmaceuticals, New York).
Clearly, the concomitant administration of yellow fever orantibody response was used as a surrogate marker to predict a
protective immune response. This approach is supported by oral polio vaccines did not affect the immune response to either
the Ty21a or CVD103-HgR vaccine strain. The study designstudies demonstrating that serum anti±S. typhi antibodies and
vibriocidal antibodies correlate with protection against typhoid did not allow us to determine if there was any effect on the
immunogenicity of the polio or yellow fever vaccines. Therefever and cholera, respectively, in ®eld trials and in volunteer
challenge studies [2, 6, 15±17]. Many antimalarial drugs, such has been some concern that immunization with live oral attenu-
ated vaccines may elevate local gut interferon levels, whichas chloroquine, me¯oquine, and proguanil, have in vitro anti-
bacterial activity that could limit in vivo replication of the could, in theory, diminish the potency of oral polio vaccine.
However, without supporting data, the Centers for Diseasevaccine strain, thereby diminishing ef®cacy. An important
®nding in the present investigation was that in vitro activity Control and Prevention found no reason to contraindicate the
simultaneous use of oral polio vaccine and Ty21a [18].of various antimalarial drugs was not predictive of their in
vivo effect upon the immune response engendered by live oral The above results illustrate that certain antimalarial drugs
can exert a detrimental effect on the immunogenicity of thevaccines.
Despite the fact that me¯oquine is highly active against the Ty21a and CVD103-HgR vaccine strains. Based on our current
®ndings, a number of recommendations can be offered. Fore-Ty21a vaccine strain in vitro (MIC, 5±10 mg/mL), it did not
exert a signi®cant negative effect on the combined serum anti± most among these are that proguanil not be administered to-
gether with Ty21a and that chloroquine not be given simultane-S. typhi IgG or IgA antibody response. The fact that chlo-
roquine also did not exert an immunosuppressive effect is not ously with CVD 103-HgR. Proguanil chemoprophylaxis should
be initiated no sooner than 10 days after the last dose of Ty21aaltogether surprising, given its high in vitro MIC (250 mg/
mL). However, the daily administration of proguanil did effect vaccine. This recommendation is based on the kinetics of the
immune response after immunization with Ty21a, when near-a marked reduction in the immune response engendered by
Ty21a even though it had a MIC (200 mg/mL) comparable maximal serum antibody responses are observed10±14 days
after completion of the vaccination regimen [9, 10]. The coad-to that of chloroquine.
The effect of antimalarial drugs on the immune response ministration of me¯oquine and Ty21a would most likely not
compromise vaccine ef®cacy. Since protection against experi-engendered by CVD103-HgR administered alone or in combi-
nation with Ty21a was more dif®cult to assess. While chlo- mental cholera is conferred as soon as 8 days after immuniza-
tion with CVD103-HgR, chloroquine prophylaxis should beroquine resulted in a signi®cant decline in both vibriocidal
seroconversion rate and GMT when given with CVD103-HgR, initiated no sooner than 8 days after vaccination [18]. While
me¯oquine effected a decrease in the vibriocidal GMT, thethis same effect was not seen when CVD103-HgR was com-
bined with Ty21a. Similarly, me¯oquine effected a decrease seroconversion rate was not signi®cantly reduced. A minimal
protective titer has yet to be determined for CVD103-HgR. Asin the vibriocidal GMT only when administered with CVD103-
HgR alone. However, the seroconversion rate in either group, noted above, the seroconversion rate was not adversely affected
by ingestion of me¯oquine. Therefore, the concomitant admin-which appears to be the best predictor of immunity to experi-
mentally induced cholera in volunteer studies [2, 16, 17], was istration of me¯oquine and CVD103-HgR would not be ex-
pected to compromise vaccine ef®cacy. Finally, if both Ty21anot adversely affected. These ®ndings may be partly attributed
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